



# First International “Michele Baccarani” Conference on CML and related diseases



February 10th-11th, 2023  
Starhotels Majestic, Turin

**Honorary President:** Giuseppe Saglio

**Organizers:** Daniela Cilloni, Giovanni Martinelli, Gianantonio Rosti

**Scientific Committee:** Massimo Breccia, Fausto Castagnetti, Claudio Cerchione, Daniela Cilloni, Carmen Fava, Robin Foà, Roberto Lemoli, Alessandro Lucchesi, Gerardo Musuraca, Cristina Papayannidis, Fabrizio Pane, Gianantonio Rosti, Domenico Russo, Giuseppe Saglio, Giorgina Specchia.

ECM accredited event: N. 2773-368974

11 ECM credits for n. 100 participants Physicians, Nurses,  
Biologists, TSLBs, Pharmacists



info@proeventi.it | www.proeventi.it

**The Conference has been accredited to the Italian Ministry of Health:**

Event n. 2773 - 368974

Provider n. 2773

**11 ECM credits** for n. 100 participants Physicians, Nurses,  
Biologists, TSLBs, Pharmacists

Each participant, to obtain ECM credits, must participate in at least 90% of the scientific work and complete the online ECM questionnaire with a total of 75% of correct answers.

Attendance will be registered via barcode reader.

# PATRONAGE



ASSOCIAZIONE ITALIANA  
CONTRO LEUCEMIE  
LINFOMI E MIELOMA

**SIE**  
Società Italiana  
di Ematologia



SERVIZIO SANITARIO REGIONALE  
EMILIA-ROMAGNA  
Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori"  
Istituto di Ricovero e Cura a Carattere Scientifico

ISTITUTO  
ROMAGNOLO  
PER LO STUDIO  
DEI TUMORI  
DINO AMADORI



**UNIVERSITÀ  
DI TORINO**



# SUMMARY

---



**6** SCIENTIFIC RATIONALE

---

**8** MICHELE BACCARANI

---

**11** SCIENTIFIC COMMITTEE

---

**12** FRIDAY, FEBRUARY 10<sup>TH</sup>

---

**16** SATURDAY, FEBRUARY 11<sup>TH</sup>

---


**19** SUPPORTED BY

---

# SCIENTIFIC

## RATIONALE

The treatment of patients with chronic myeloid leukemia (CML) highlights an evolving story. Having reached the goal of survival almost equal to that of a control population without leukemia, problems remain regarding the treatment of a small proportion of patients still resistant to therapy with currently available BCR-ABL inhibitors (TKIs) and therefore still at risk of dying from disease-related causes, long-term toxicity problems due to continuous TKI intake, the need to increase the percentage of patients who can maintain a continuous remission even in the absence of TKI therapy (TFR), and the quality of life of patients. The meeting, dedicated to the most influential and distinguished Italian hematologist of the past decades in the field of CML, Prof. Michele Baccharani, one year after his passing, is aimed at establishing an exchange of views and experiences between CML physicians in Italy and leading European KOLs to focus on the most important points and projects to be explored in the near future regarding CML.



# MICHELE BACCARANI

## BIOGRAPHY



### **PROF. MICHELE BACCARANI (1942 - 2021)**

Born in Bologna, 08/16/1942. Graduated in Medicine and Surgery, University of Bologna, 1966. Specialization in Blood Diseases, University of Modena, 1969. Research fellow, University of Bologna 1968-1970, University of Copenhagen, 1971. Assistant and assistant professor at the "L. and A. Seràgnoli" Institute of Hematology, University of Bologna, 1972-1985. Professor of Hematology, University of Trieste, 1986. Full Professor of Hematology and Director, Hematology Clinic, University of Udine, 1987 to 2000. Founder and Coordinator of the Department for Bone Marrow Transplantation, Udine from 1995 to 2000. Coordinator of the Coop. Italiano per lo Studio della Leucemia Mieloide Cronica (now CML Working Party of GIMEMA) since 1989. Vice dean of the Faculty of Medicine of the University of Bologna from 2001 to 2007. Full Professor of Haematology, University of Bologna and Director of the Institute of Haematology "L. e A. Seràgnoli", Integrated Care Department of Haematology, Oncology and Laboratory Medicine, Policlinico S.Orsola-Malpighi, Azienda Ospedaliero-Universitaria di Bologna, since 1.11.2000. Director of the Complex Unit of the Institutes of Cardiology and Hematology from November 1, 2004 to January 31, 2008. Director of the University Department of Hematology and Oncological Sciences "L. and A. Seràgnoli". Coordinator of the Center for the Study of Stem Cells at Policlinico S. Orsola-Malpighi, Bologna Hospitals, since May 2004. President of the Italian Society of Experimental Hematology 1995-1996. President of the Italian Society of Hematology 2002-2003. Main areas of research and clinical activity: acute leukemias, chronic myeloid leukemia, malignant lymphomas, cell kinetics, cancer chemotherapy, antiproliferative drug resistance mechanisms, allogeneic and autologous bone marrow transplantation.



# HONORARY

## PRESIDENT

Giuseppe Saglio

# ORGANIZERS



Daniela Cilloni

Giovanni Martinelli

Gianantonio Rosti

# SCIENTIFIC

## COMMITTEE

Massimo **Breccia**

Rome

Fausto **Castagnetti**

Bologna

Claudio **Cerchione**

Meldola (FC)

Daniela **Cilloni**

Turin

Carmen **Fava**

Turin

Robin **Foà**

Rome

Roberto **Lemoli**

Genoa

Alessandro **Lucchesi**

Meldola (FC)

Gerardo **Musuraca**

Meldola (FC)

Fabrizio **Pane**

Naples

Cristina **Papayannidis**

Bologna

Gianantonio **Rosti**

Meldola (FC)

Domenico **Russo**

Brescia

Giuseppe **Saglio**

Turin

Giorgina **Specchia**

Bari



**13.30 PRESENTATION OF THE MEETING**

Giovanni Martinelli, Fabrizio Pane

**13.40 Inaugural Lecture:**

Chairman: Claudio Cerchione

How we treat CML patients at MdAnderson in 2023

**Hagop Kantarjian**

**14.00 THE CML CAMPUS PROJECT: OBSERVATIONAL STUDIES ON CML CLINICAL PRACTICE IN ITALY**

Chairmen and introduction: Massimo Breccia, Giorgina Specchia

**14.00** Observational study on the CML treatment in Italy

**Giorgina Specchia**

**14.15** First-line CML treatment in Italy

**Patrizia Pregno**

**14.30** Switching TKI therapy: when and how in clinical practice in Italy

**Giovanna Rege-Cambrin**

**14.45** Pregnancy and CML in the Italian experience

**Elisabetta Abruzzese**

**15.00** Dosages of TKIs in real life clinical practice

**Alessandra Iurlo**

**15.15** Cardiovascular TKI toxicity

**Giovanni Caocci**

**15.30** CML Third-line treatment in Italy

**Fabio Stagno**

**15.45** CML in the elderly

**Roberto Latagliata**

**16.00** Allograft in CML: when and how

**Antonella Gozzini**

**16.15** Second neoplasias in TKI treated CML patients: an emerging problem?  
**Francesco Autore**

**16.30** **Coffee Break**

**16.50** **Lecture:**

Chairman: Giuseppe Saglio  
The transition from interferon to TKI therapy  
**Carlo Gambacorti Passerini**

**17.10** **GIMEMA CLINICAL TRIALS AND OTHER INVESTIGATOR INITIATED  
CLINICAL TRIALS IN ITALY**

Chairmen: Fausto Castagnetti, Fabrizio Pane

**17.10** The commitment of the GIMEMA WP on MPNs for clinical research in  
CML  
**Fabrizio Pane**

**17.25** Sustrenim Study  
**Fabrizio Pane**

**17.40** The Best trial  
**Fausto Castagnetti**

**17.55** Dante study  
**Gabriele Gugliotta**

**18.10** Asciminib, real life experience in Italy  
**Massimo Breccia**

**18.25** TKIs and interferons, where are we going?  
**Luigia Luciano**

**18.40 LEUKEMIC STEM CELLS**

***SESSION DEDICATED TO TESSA HOLYOAKE***

Chairman and introduction: Giovanni Martinelli

**18.40 Hematopoietic Stem Cell Diseases**

**Alessandro Lucchesi**

**18.55 Specific and not specific Phenotypic markers as potential targets to hit LSCs**

**Monica Bocchia**

**19.10 Metabolic vulnerability of LSCs**

**Valentina Gaidano**

**19.25 Lecture:**

Chairman: Claudio Cerchione

Systemic Mastocytosis, a no more neglected disease

**Daniela Cilloni**

**19.40 End of Day 1**



**08.00 ROLE OF THE MOLECULAR BIOLOGY LAB IN THE TREATMENT OF CML**

Chairmen: Francesco Di Raimondo, Roberto Lemoli

**08.00** The LabNet model  
**Enrico Gottardi, Barbara Izzo**

**08.15** Importance of the early detection of the T315I and of the compound mutations for the right choice in the selection of the second line therapy  
**Simona Soverini**

**08.30** ddPCR in CML, will this become routine?  
**Sara Galimberti**

**08.45 TFR: THE ITALIAN AND EUROPEAN EXPERIENCE**

Chairmen: Rudiger Hehlmann, Domenico Russo

**08.45** The pioneer French experience  
**Francois-Xavier Mahon**

**09.00** Euroski, the latest update  
**Susanne Saussele**

**09.15** Intermittent imatinib: the OPT-kIMA trial  
**Michele Malagola**

**09.30** Real life observational studies  
**Carmen Fava**

**09.45** 2<sup>nd</sup> generation TKIs and TFR  
**Mario Tiribelli**

**10.00** In TKIs discontinuation are we following the correct scheme?  
**Massimiliano Bonifacio**

**10.15 Coffee Break**



**10.30 "MICHELE BACCARANI LECTURES"**

Chairmen: Gerardo Musuraca, Gianantonio Rosti

**10.30** Tribute to my professor Michele Bacarani  
**Gianantonio Rosti**

**10.50** The impact of ACA arising in the course of CML  
**Rudiger Hehlmann**

**11.10** Allogeneic transplant in CML: when and how  
**Jane Apperley**

**11.30** Generic TKIs: will they change our approach to CML therapy  
**Tomasz Sacha**

**11.50** Are we using the correct sequence in TKI therapy?  
**Franck Nicolini**

**12.10** Lessons derived from CML in the management of MPNs  
**Tariq Mughal**

**12.30** Clinical and Biological lessons learned from CML  
**Robert Peter Gale**

**12.50 THE CML ADVOCATES ASSOCIATIONS**

Chairman and introduction: Felice Bombaci

**12.55** The importance of the quality of life for CML patients  
**Fabio Efficace**

**13.15 Lunch Time**

**14.00 PH-POSITIVE ALLS**

Chairmen: Robin Foà, Giovanni Martinelli

**14.00** How the chemo-free story in Ph+ ALL started and the role played by Michele Bacarani

**Robin Foà**

**14.20** Ph-positive ALLs: Another curable leukemia without chemotherapy?

**Giovanni Martinelli**

**14.40** The D-Alba protocol: after 4 years follow up

**Sabina Chiaretti**

**15.00** How I treat Ph-positive ALLs at MDAnderson in 2023

**Elias Jabbour**

**15.20** Moab and bispecific in the Ph+ R/R ALL: the Neverending History

**Cristina Papayannidis**

**15.50** Take home messages and end of the meeting

**Giuseppe Saglio**

# SUPPORTED BY

AN UNRESTRICTED EDUCATIONAL GRANT FROM



Graphic Designer: **Mario Titone**

Turin | February 10th-11th, 2023

